Among them, our data suggest that celastrol and pristimerin have greater anti-tumor efficacy but also greater toxicity both in vitro and in vivo (observed as lower IC50 to normal hepatocytes in vitro and greater weight loss in vivo); whereas cel-D2 and cel-D7 have slightly reduced anti-tumor efficacy and reduced toxicity (observed as higher IC50 to normal hepatocytes in vitro and absence of weight loss in vivo). Here, CEL is linked to neoplasm.